EYEMATE System for Remote Glaucoma Management Obtains FDA Breakthrough Device Designation

What Kind of Equipment is Used to Analyze DNA?

Below are some of a few basic processes followed throughout DNA testing. The general procedure entails:  • Isolating DNA from a sample containing the needed...

mJOULE Launches in the United Kingdom Reports Sciton

"Sciton is dedicated to worldwide support and growth. We continue to demonstrate our commitment to developing high quality devices and marketing efforts for our physician and medspa partners worldwide." says Lacee J. Naik, Vice President of Marketing and Public Relations.

FDA Issues Draft Guidance on Remanufacturing and Discussion Paper Seeking Feedback on Cybersecurity Servicing of Medical Devices

With this in mind, the FDA is issuing today's draft guidance to help clarify whether activities performed on medical devices are likely remanufacturing as well as a discussion paper on cybersecurity servicing of devices.

EYEMATE system for digitally-enabled remote patient monitoring and management of glaucoma has obtained Breakthrough Device Designation (BDD) from the U.S. Food and Drug Administration (FDA).

A BDD is only assigned for breakthrough technologies that have the potential to provide more effective treatment of life-threatening or irreversibly debilitating diseases in order to provide patients and physicians more timely access to such technologies without compromising safety.

The patented EYEMATE system is the world’s only clinically-validated product used for comprehensive remote glaucoma monitoring. It empowers patients with the ability to measure their intraocular pressures from anywhere and anytime, and then automatically send that information in real-time to their doctor. This information empowers doctors to adjust glaucoma therapy based on a patient’s current condition rather than make therapeutic adjustments only during an office visit.

Max G. Ostermeier, CEO and Founder of Implandata states: “We are extremely pleased to move forward under the FDA BDD program, as we will benefit from additional FDA input during the premarket development as well during the submission process and through an expedited review once the submission is filed. With FDA market authorization, the EYEMATE system will now be entitled to Medicare Coverage of Innovative Technology for at least 4 years, offering beneficiaries predictable access to the breakthrough EYEMATE system, helping to improve their health outcomes.”

Robert N. Weinreb, M.D., Chair and Distinguished Professor of Ophthalmology at University of California, San Diego and Implandata Medical Advisor stresses: “The BDD for the EYEMATE system is exciting news. It is an important step towards developing a digital platform for using intraocular pressure and other diagnostic data to enhance management of glaucoma patients.”

Kaweh Mansouri, M.D., M.P.H, Consultant Ophthalmologist at Clinique de Montchoisi Lausanne/Switzerland, Adjoint Professor at the Department of Ophthalmology, University of Colorado, Denver, and Implandata’s Chief Medical Officer elaborates: “Our clinical experience with the EYEMATE system in Europe has been very positive as evidenced by over a 100.000 pressure readings that have been taken by patients who have had the EYEMATE sensor implanted. The real-life information provided by the EYEMATE system enables eye care specialists to better understand a patients’ disease and to apply more effective treatments in a timely fashion. And patients are empowered via self-monitoring, resulting in improved therapy adherence.”



Hyperfine Adds Medtech Leader and Visionary Scott Huennekens as Executive Chairman

Mr. Huennekens’ public boards include Chairman of Acutus Medical (IPO August 2020); Chairman of Envista (IPO September 2019); and board member of Nuvasive. He also serves as a board member and past Chairman of the Medical Device Manufacturer’s Association (MDMA).

One Drop Reports Carrie Siragusa, CPA Appointed VP of Commercial Strategy, Biosensor

Formerly Head of Innovation and Diabetes Portfolio at Sanofi, Siragusa will be part of a team bringing a multi-analyte dermal sensor (biosensor) with continuous health sensing capabilities to market with a mission to provide broader access to continuous glucose monitoring.

Barbara Moorhouse Appointed as Medica Non-Executive Director

Barbara has extensive business and management experience in the private, public, and regulated sectors.

Subscribe to Medical Device News Magazine here.

Related Articles